[Show abstract][Hide abstract] ABSTRACT: In recent years, abnormal regulation of the endocannabinoid system (ECS) has been proposed as a key factor in the development of obesity-related metabolic disorders such as diabetes. Indeed, this signaling system which includes the cannabinoid type 1 and 2 receptors (CB1R and CB2R) and their endogenous lipid ligands, has been shown to inﬂuence feeding behavior, energy expenditure, as well as glucose and lipid metabolism. Importantly, blocking CB1R function has been demonstrated to counteract metabolic aberrations associated with obesity in various murine models and in humans. Here we provide an update on recent ﬁndings describing the role of the ECS in energy balance and metabolism, and explore how recent experimental and clinical studies have delivered new insights into the therapeutic potential of this physiological system as a means of treating obesity-induced metabolic disorders. WIREs Membr Transp Signal 2013, 2:49–63. doi: 10.1002/wmts.79 For further resources related to this article, please visit the WIREs website.
Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 03/2013; 2(2).
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.